1Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy [J]. Am J Med, 1998,105:31-38.
2Tramner MR, Moore RA, Reynolds DJ, et al Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSALD use[J]. Pain, 2000,85:169-182.
3Tramer MR,Moore RA,Reynolds DJ,et al.Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use[].Pain.2000
4Bombardier C.An evidence-based evaluation of the gastrointestinal safety of coxibs[].The American Journal of Cardiology.2002
5Singh G.Recent considerations in nonsteroidal anti-inflammatory drug gastropathy[].The American Journal of Medicine.1998
6Raz A,Wyche A,Fagan D,et al.The cell biology of fibroblast cyclooxygenase[].Advances in Experimental Medicine and Biology.1989
7Singh G,Triadafilopoulos G.Epidemiology of NSAID induced gastrointestinal complications[].The Journal of Rheumatology.1999
8Fu JY,Masferrer JL,Seibert K,et al.The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes[].Journal of Biological Chemistry.1990
9Bensen WG,Zhao SZ,Burke TA,et al.Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo[].The Journal of Rheumatology.2000
8Upul K Bandarage,Liqing Chen,Xinqin Fang,et al.Nitrosothiol Esters of Diclofenae:Synthesis and Pharmacological characterization as Gastrointestinal sparing prodmgs[J].J Med Chem,2000,43:4005-4016.
